AstraZeneca PLC (AZN)

29.35
NYSE : Health Care
Prev Close 29.51
Day Low/High 29.20 / 29.36
52 Wk Low/High 25.55 / 35.04
Avg Volume 7.34M
Exchange NYSE
Shares Outstanding 2.53B
Market Cap 74.66B
EPS 1.40
P/E Ratio 13.23
Div & Yield 1.90 (6.40%)

Latest News

Clovis, Tesaro Soar on Astrazeneca Phase Three News

Clovis, Tesaro Soar on Astrazeneca Phase Three News

AstraZeneca shares, meanwhile, were less-than-moved by the news.

European Benchmarks Fall, But London Bucks Trend on Takeover Activity

European Benchmarks Fall, But London Bucks Trend on Takeover Activity

Kraft Heinz's offer for Unilever boosted the FTSE 100 in London, but markets were in the red elsewhere.

Stocks Drift Lower in Quieter Trading After the Week's Record Run

Stocks Drift Lower in Quieter Trading After the Week's Record Run

Wall Street is mostly lower in a quieter end to a record-breaking week in which stocks scored their best winning streak in a quarter century.

Wall Street Looks Set to Open Lower as Stock Futures Retreat Again

Wall Street Looks Set to Open Lower as Stock Futures Retreat Again

Stock futures retreat again on Friday, looking to close out the week on a bum note following Wall Street's best record-breaking run in a quarter century.

AstraZeneca Stock Rises On Successful Breast Cancer Drug Trial

AstraZeneca Stock Rises On Successful Breast Cancer Drug Trial

Astrazeneca stock rose Friday after the company said that its Lynparza drug fared well in clinical trials of its effectiveness as a breast cancer treatment.

LYNPARZA™ (olaparib) Meets Primary Endpoint In Phase III Trial In BRCA-Mutated Metastatic Breast Cancer

LYNPARZA™ (olaparib) Meets Primary Endpoint In Phase III Trial In BRCA-Mutated Metastatic Breast Cancer

AstraZeneca today announced positive results from its Phase III OlympiAD trial comparing LYNPARZA™ (olaparib) tablets (300mg twice daily) to physician's choice of a standard of care chemotherapy in the treatment of...

European Benchmarks Fall on Weak Earnings and Ex-Dividends

European Benchmarks Fall on Weak Earnings and Ex-Dividends

Weak earnings and ex-dividend dates drove a correction in stock markets across Europe.

European Stocks Drift Lower, Airlines Lead Benchmark Gainers After Air France Earnings

European Stocks Drift Lower, Airlines Lead Benchmark Gainers After Air France Earnings

European stocks drifted lower Thursday despite a strong session in Asia as a U.S. dollar retreat and mixed corporate earnings allowed benchmarks to pull back from recent multi-month highs.

European Stocks Called Higher, ex-Dividend Shares to Weigh on FTSE

European Stocks Called Higher, ex-Dividend Shares to Weigh on FTSE

European stocks are expected to open mixed Thursday following a solid session in Asia and a pullback for the U.S. dollar.

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.

Eli Lilly Is Great Stock to Buy Now

Eli Lilly Is Great Stock to Buy Now

Here's why the pharmaceutical company is a solid addition to your portfolio.

Cramer: Allergan Is the New Pharma Growth Stock

Cramer: Allergan Is the New Pharma Growth Stock

Jim Cramer compares Allergan's growth to other pharma stocks.

Brexit Already Having a Negative Impact, Business Leaders Say

Brexit Already Having a Negative Impact, Business Leaders Say

The U.K.'s top business leaders have painted a pessimistic view of Brexit, with more than half of respondents in a survey saying that it is already having a negative impact.

Acadia Pops on Takeout Rumors, But Don't Buy on M&A Just Yet

Acadia Pops on Takeout Rumors, But Don't Buy on M&A Just Yet

The company's shares jumped 5% midday Friday on rumors that Astrazeneca could buy Acadia.

Iran, Oil, Solid U.S. Jobs Data Outweigh Chinese Rate Hike for European Stocks

Iran, Oil, Solid U.S. Jobs Data Outweigh Chinese Rate Hike for European Stocks

Benchmarks in Europe were broadly higher after new Iran sanctions boosted oil, while investors focus on corporate earnings and solid jobs data.

European Stocks Shrug Off China Rate Increase, Await U.S. Payroll Data

European Stocks Shrug Off China Rate Increase, Await U.S. Payroll Data

European investors looked past weaker manufacturing data and a rate hike from China Friday, preferring to focus on a key jobs report from the U.S. later in the session.

AstraZeneca Provides Cautious 2017 Guidance

AstraZeneca Provides Cautious 2017 Guidance

AstraZeneca posted stronger-than-expected earnings in the fourth quarter but was hesitant about 2017.

News Out of Europe: Reckitt Benckiser Confirms $16.7 Billion Mead Johnson Approach

News Out of Europe: Reckitt Benckiser Confirms $16.7 Billion Mead Johnson Approach

Here is a round-up of the headlines from Europe.

AstraZeneca Falls After Cautious 2017 Outlook as Crestor Sales Slow

AstraZeneca Falls After Cautious 2017 Outlook as Crestor Sales Slow

AstraZeneca posted stronger-than-expected earnings in the fourth quarter but provided cautious 2017 guidance as its blockbuster Crestor drug sales continued to slow in the face of generic competition.

All Eyes on Growth Plans as Pfizer Gears Up for Fourth Quarter Earnings

All Eyes on Growth Plans as Pfizer Gears Up for Fourth Quarter Earnings

Investors will be listening for details around competition facing key products and plans for capital deployment.

Bristol-Myers Squibb, Where Art Thou? Not in First-Line Lung Cancer Immunotherapy, Sadly

Bristol-Myers Squibb, Where Art Thou? Not in First-Line Lung Cancer Immunotherapy, Sadly

Bristol-Myers suffered another setback when the pharma giant said it would not seek accelerated approval for a combination of two immunotherapy drugs as a treatment for newly diagnosed lung cancer.

5 Things You Must Know Before the Market Opens Thursday

5 Things You Must Know Before the Market Opens Thursday

U.S. stock futures and shares in London and Asia fall Thursday after Donald Trump offers few details on his policies during his first press conference since winning the U.S. election.

European Pharma Shares Hammered After Trump Press Conference Attack

European Pharma Shares Hammered After Trump Press Conference Attack

European health care and pharmaceutical company shares were hit hard Thursday after President-elect Donald Trump accused some firms of 'getting away with murder' in his Wednesday press conference.

Bristol-Myers and AstraZeneca Take Beatings

Bristol-Myers and AstraZeneca Take Beatings

It happened in the wake of Merck's latest drug approval.

Bullish and Bearish Reversals in the Market

Bullish and Bearish Reversals in the Market

These companies show signs of a change of direction.

Shell, AstraZeneca Could Surprise in 2017, Credit Suisse Says

Shell, AstraZeneca Could Surprise in 2017, Credit Suisse Says

AstraZeneca and Royal Dutch Shell will surprise investors.

Here's Why General Motors Is One of Wednesday's Most Active Stocks

Here's Why General Motors Is One of Wednesday's Most Active Stocks

GM, Bank of America and AstraZeneca are among today's active movers. Here's how to trade them.